Fig. 5: Association of objective response with PD-L1 expression as assessed by artificial intelligence-powered and manual scoring methods. | Modern Pathology

Fig. 5: Association of objective response with PD-L1 expression as assessed by artificial intelligence-powered and manual scoring methods.

From: Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab

Fig. 5

For CheckMate 026, only patients with a PD-L1 expression level ≥1% underwent randomization and were stratified according to a PD-L1 expression level of < or ≥5%. No response data are available for the adjuvant CheckMate 238 study, which was therefore excluded from this analysis. CI confidence interval, CR complete response, IPI ipilimumab, MEL melanoma, NIVO nivolumab, NSCLC non-small cell lung cancer, ORR objective response rate, PD-L1 programmed death ligand 1, PR partial response, SCCHN squamous cell carcinoma of the head and neck, TC tumor cell, UC urothelial carcinoma.

Back to article page